Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF plus rituximab in previously untreated follicular lymphoma
2007-005580-95Phase 2Active
- Sponsor
- Goelams
- Start
- Jul 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and sargramostim in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL), sponsored by Goelams. Primary endpoint: Overall response rate after induction. Started Jul 2008; status: active.
02
Drugs
rituximabsargramostim
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2007-005580-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005580-95.